Drug intelligence / Profile preview

DA-4531

Development stage: Preclinical
Lead developer: Dong-A ST
Modality: Small Molecules

Overview

DA-4531 is a preclinical-stage small molecule being developed by Dong-A ST for the treatment of various cancers. As of current pipeline disclosures, the specific biological target of DA-4531 remains undisclosed, though it is categorized within the company's oncology research programs. The drug is part of Dong-A ST's effort to expand its portfolio of targeted therapies and is currently undergoing early-stage evaluation to determine its safety and efficacy profile for potential clinical advancement.

Beyond the preview

Go deeper on DA-4531.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-4531.

Explore the full profile